Galapagos reports additional Phase IIb filgotinib data in RA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported 24-week data from the Phase IIb DARWIN 1 trial of filgotinib ( GLPG0634) to treat rheumatoid arthritis (RA) that suggested a differentiated safety profile; the data were in line with 12-week results. Galapagos

Read the full 382 word article

How to gain access

Continue reading with a
two-week free trial.